| scholarly article | Q13442814 |
| P2093 | author name string | L M Hutt-Fletcher | |
| C M Lake | |||
| C M Borza | |||
| S M Turk | |||
| S J Molesworth | |||
| P2860 | cites work | Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted | Q24655638 |
| B cell activation and the establishment of Epstein-Barr virus latency | Q28281625 | ||
| Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect | Q33781911 | ||
| Epstein-Barr virus recombinant lacking expression of glycoprotein gp150 infects B cells normally but is enhanced for infection of epithelial cells. | Q33784012 | ||
| Epstein-Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells | Q33784997 | ||
| Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor | Q33799317 | ||
| DNA sequence and expression of the B95-8 Epstein-Barr virus genome. | Q34245077 | ||
| The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells. | Q35840624 | ||
| A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells | Q35864616 | ||
| The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation | Q35866482 | ||
| Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes | Q35886960 | ||
| Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2 | Q36273277 | ||
| Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen | Q36390855 | ||
| Characterization and expression of a glycoprotein encoded by the Epstein-Barr virus BamHI I fragment | Q36806682 | ||
| Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells | Q36831966 | ||
| Identification of the Epstein-Barr virus gp85 gene | Q36865571 | ||
| Induction of antibodies to the Epstein-Barr virus glycoprotein gp85 with a synthetic peptide corresponding to a sequence in the BXLF2 open reading frame | Q36865623 | ||
| A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus. | Q36871887 | ||
| Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. | Q36887333 | ||
| Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2) | Q36903213 | ||
| CD21-Dependent infection of an epithelial cell line, 293, by Epstein-Barr virus. | Q39551815 | ||
| Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells | Q39578660 | ||
| Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells | Q39876626 | ||
| Epstein-Barr virus infection of human gastric carcinoma cells: implication of the existence of a new virus receptor different from CD21. | Q39880437 | ||
| Glycoprotein H of pseudorabies virus is essential for entry and cell-to-cell spread of the virus | Q40066036 | ||
| Detection of circular and linear herpesvirus DNA molecules in mammalian cells by gel electrophoresis. | Q40139467 | ||
| Nasopharyngeal carcinoma: the Epstein-Barr virus association | Q40765526 | ||
| Bovine herpesvirus 1 requires glycoprotein H for infectivity and direct spreading and glycoproteins gH(W450) and gB for glycoprotein D-independent cell-to-cell spread | Q40975080 | ||
| Bovine herpesvirus type 1 glycoprotein H is essential for penetration and propagation in cell culture | Q41014421 | ||
| Epstein-Barr virus and the B cell: that's all it takes | Q41051454 | ||
| Glycoprotein gH of pseudorabies virus is essential for penetration and propagation in cell culture and in the nervous system of mice. | Q41171867 | ||
| Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2). | Q41211049 | ||
| Epstein-Barr virus glycoprotein gp85 associates with the BKRF2 gene product and is incompletely processed as a recombinant protein | Q41535520 | ||
| Sequence and transcription of Raji Epstein-Barr virus DNA spanning the B95-8 deletion region | Q41716583 | ||
| Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis | Q43974065 | ||
| Detection of Epstein-Barr virus in invasive breast cancers. | Q45747752 | ||
| Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines | Q45797211 | ||
| Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion | Q45837679 | ||
| Epstein-Barr virus infection and replication in a human epithelial cell system | Q45880200 | ||
| Epstein-Barr virus and gastric carcinoma | Q93889525 | ||
| P433 | issue | 14 | |
| P921 | main subject | virus | Q808 |
| Epstein–Barr virus | Q6900 | ||
| P304 | page(s) | 6324-6332 | |
| P577 | publication date | 2000-07-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells | |
| P478 | volume | 74 |
| Q39736774 | A functional YNKI motif in the short cytoplasmic tail of varicella-zoster virus glycoprotein gH mediates clathrin-dependent and antibody-independent endocytosis |
| Q33648958 | A human cytomegalovirus gO-null mutant fails to incorporate gH/gL into the virion envelope and is unable to enter fibroblasts and epithelial and endothelial cells |
| Q33287194 | A molecular link between malaria and Epstein-Barr virus reactivation |
| Q39736828 | A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. |
| Q40727982 | Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus |
| Q52317335 | An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus. |
| Q37033353 | Analysis of Epstein-Barr virus glycoprotein B functional domains via linker insertion mutagenesis |
| Q35101331 | Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells |
| Q28542501 | Assembly and architecture of the EBV B cell entry triggering complex |
| Q47137780 | B Cell Receptor Activation and Chemical Induction Trigger Caspase-Mediated Cleavage of PIAS1 to Facilitate Epstein-Barr Virus Reactivation. |
| Q89717789 | B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection |
| Q35948061 | Binding-site interactions between Epstein-Barr virus fusion proteins gp42 and gH/gL reveal a peptide that inhibits both epithelial and B-cell membrane fusion. |
| Q34094547 | Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair |
| Q28552274 | CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections |
| Q59336899 | Calcium mobilization is responsible for Thapsigargin induced Epstein Barr virus lytic reactivation in immortalized lymphoblstoid cell lines |
| Q37713781 | Cell-surface expression of a mutated Epstein-Barr virus glycoprotein B allows fusion independent of other viral proteins |
| Q33790326 | Characteristics of Epstein-Barr virus envelope protein gp42. |
| Q36253674 | Characterization of EBV gB indicates properties of both class I and class II viral fusion proteins |
| Q45362064 | Characterization of Epstein-Barr virus gp350/220 gene variants in virus isolates from gastric carcinoma and nasopharyngeal carcinoma |
| Q38307961 | Characterization of the Epstein-Barr virus glycoprotein BMRF-2. |
| Q42631734 | Characterization of the Herpesvirus saimiri Orf51 protein |
| Q58696468 | Co-localization of and interaction between duck enteritis virus glycoprotein H and L |
| Q38812531 | Comparative Mutagenesis of Pseudorabies Virus and Epstein-Barr Virus gH Identifies a Structural Determinant within Domain III of gH Required for Surface Expression and Entry Function |
| Q59192439 | Comparative method of protein expression and isolation of EBV epitope in E.coli DH5α |
| Q36676670 | Compatibility of the gH homologues of Epstein-Barr virus and related lymphocryptoviruses |
| Q24540310 | Complete nucleotide sequence of the rhesus lymphocryptovirus: genetic validation for an Epstein-Barr virus animal model |
| Q91770815 | Conserved Herpesvirus Protein Kinases Target SAMHD1 to Facilitate Virus Replication |
| Q34302078 | Contribution of C/EBP proteins to Epstein-Barr virus lytic gene expression and replication in epithelial cells |
| Q39455821 | DNA Oncogenic Virus-Induced Oxidative Stress, Genomic Damage, and Aberrant Epigenetic Alterations |
| Q35941628 | Deregulation of the cell cycle by the Epstein-Barr virus |
| Q90380860 | Development of an Improved Epstein-Barr Virus (EBV) Neutralizing Antibody Assay to Facilitate Development of a Prophylactic gp350-Subunit EBV Vaccine |
| Q35797164 | Differentiation-Dependent KLF4 Expression Promotes Lytic Epstein-Barr Virus Infection in Epithelial Cells |
| Q40339509 | Differentiation-Dependent LMP1 Expression Is Required for Efficient Lytic Epstein-Barr Virus Reactivation in Epithelial Cells |
| Q40178497 | Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation |
| Q90571096 | EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers |
| Q38912277 | EBV glycoproteins: where are we now? |
| Q26783764 | Emerging Vaccine Technologies |
| Q56904286 | Emerging and re-emerging infectious disease in otorhinolaryngology |
| Q35038289 | Entry of viruses through the epithelial barrier: pathogenic trickery |
| Q47559100 | Ephrin receptor A2 is a functional entry receptor for Epstein-Barr virus. |
| Q90481053 | Epithelial cell infection by Epstein-Barr virus |
| Q38076138 | Epstein-Barr Virus (EBV)-associated gastric carcinoma |
| Q39943472 | Epstein-Barr Virus (EBV): infection, propagation, quantitation, and storage |
| Q92734569 | Epstein-Barr Virus Infection Promotes Epithelial Cell Growth by Attenuating Differentiation-Dependent Exit from the Cell Cycle |
| Q59351211 | Epstein-Barr virus BORF2 inhibits cellular APOBEC3B to preserve viral genome integrity |
| Q35947541 | Epstein-Barr virus entry |
| Q34593777 | Epstein-Barr virus glycoprotein gB and gHgL can mediate fusion and entry in trans, and heat can act as a partial surrogate for gHgL and trigger a conformational change in gB. |
| Q36600329 | Epstein-Barr virus glycoprotein gM can interact with the cellular protein p32 and knockdown of p32 impairs virus. |
| Q33900772 | Epstein-Barr virus infection of polarized epithelial cells via the basolateral surface by memory B cell-mediated transfer infection. |
| Q24294987 | Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells |
| Q34717579 | Epstein-Barr virus shed in saliva is high in B-cell-tropic glycoprotein gp42. |
| Q33826978 | Epstein-Barr virus that lacks glycoprotein gN is impaired in assembly and infection |
| Q36978584 | Epstein-Barr virus transcytosis through polarized oral epithelial cells |
| Q26824570 | Epstein-Barr virus-associated lymphoid malignancies: the expanding spectrum of hematopoietic neoplasms |
| Q34613494 | Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding |
| Q33866311 | Establishment of latent Epstein-Barr virus infection and stable episomal maintenance in murine B-cell lines |
| Q35622700 | Fusing structure and function: a structural view of the herpesvirus entry machinery |
| Q35599292 | Fusion of Epstein-Barr virus with epithelial cells can be triggered by αvβ5 in addition to αvβ6 and αvβ8, and integrin binding triggers a conformational change in glycoproteins gHgL. |
| Q37453542 | Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins alphavbeta6 or alphavbeta8. |
| Q45453152 | Fusogenic domains in herpes simplex virus type 1 glycoprotein H. |
| Q35184458 | Gamma herpesviruses: pathogenesis of infection and cell signaling |
| Q34261921 | Genome-wide DNA methylation as an epigenetic consequence of Epstein-Barr virus infection of immortalized keratinocytes |
| Q34575025 | Glycoprotein L disruption reveals two functional forms of the murine gammaherpesvirus 68 glycoprotein H. |
| Q47550353 | Herpesvirus deconjugases inhibit the IFN response by promoting TRIM25 autoubiquitination and functional inactivation of the RIG-I signalosome. |
| Q89599383 | Heterogeneous Responses of Gastric Cancer Cell Lines to Tenovin-6 and Synergistic Effect with Chloroquine |
| Q37100066 | High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma |
| Q37123188 | Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells |
| Q33649006 | Human cytomegalovirus TR strain glycoprotein O acts as a chaperone promoting gH/gL incorporation into virions but is not present in virions |
| Q28551855 | Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial Malignancies |
| Q36015054 | Imaging virus-associated cancer. |
| Q35665954 | Important but differential roles for actin in trafficking of Epstein-Barr virus in B cells and epithelial cells |
| Q34348276 | In vivo function of a gammaherpesvirus virion glycoprotein: influence on B-cell infection and mononucleosis |
| Q35823798 | In-cell infection: a novel pathway for Epstein-Barr virus infection mediated by cell-in-cell structures. |
| Q36782473 | Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib |
| Q36066487 | Infection of Epstein-Barr virus in a gastric carcinoma cell line induces anchorage independence and global changes in gene expression |
| Q33603682 | Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands |
| Q37358334 | Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide |
| Q38849926 | Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir |
| Q35635291 | Inhibition of heavy chain and beta2-microglobulin synthesis as a mechanism of major histocompatibility complex class I downregulation during Epstein-Barr virus replication |
| Q36759769 | Interactions of the Kaposi's Sarcoma-associated herpesvirus nuclear egress complex: ORF69 is a potent factor for remodeling cellular membranes |
| Q60959616 | Intracellular Iron Chelation by a Novel Compound, C7, Reactivates Epstein⁻Barr Virus (EBV) Lytic Cycle via the ERK-Autophagy Axis in EBV-Positive Epithelial Cancers |
| Q45399777 | Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21). |
| Q92381594 | Kaposi Sarcoma-Associated Herpesvirus Glycoprotein H Is Indispensable for Infection of Epithelial, Endothelial, and Fibroblast Cell Types |
| Q36764365 | Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV. |
| Q33360874 | Laser-capture microdissection of oropharyngeal epithelium indicates restriction of Epstein-Barr virus receptor/CD21 mRNA to tonsil epithelial cells |
| Q34226611 | Lytic viral replication as a contributor to the detection of Epstein-Barr virus in breast cancer |
| Q34120826 | Mapping the N-terminal residues of Epstein-Barr virus gp42 that bind gH/gL by using fluorescence polarization and cell-based fusion assays |
| Q42477461 | Marginal periodontium as a potential reservoir of human papillomavirus in oral mucosa |
| Q39798789 | Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication |
| Q34597080 | Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350. |
| Q37730255 | Murine gammaherpesvirus 68 lacking gp150 shows defective virion release but establishes normal latency in vivo. |
| Q33930429 | Mutations of Epstein-Barr virus gH that are differentially able to support fusion with B cells or epithelial cells |
| Q35119824 | Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells |
| Q98159796 | Neutralizing Antibodies Protect against Oral Transmission of Lymphocryptovirus |
| Q36055637 | Nonmuscle myosin heavy chain IIA mediates Epstein-Barr virus infection of nasopharyngeal epithelial cells |
| Q37745980 | Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice |
| Q34237606 | Oral dysplasia and squamous cell carcinoma: correlation between increased expression of CD21, Epstein-Barr virus and CK19. |
| Q35026045 | Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders |
| Q92152951 | Pharmacologic Activation of Lytic Epstein-Barr Virus Gene Expression without Virion Production |
| Q34598541 | Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells |
| Q34741938 | Rhesus and human cytomegalovirus glycoprotein L are required for infection and cell-to-cell spread of virus but cannot complement each other |
| Q37145249 | Self-assembly of Epstein-Barr virus capsids. |
| Q35101434 | Soluble Epstein-Barr virus glycoproteins gH, gL, and gp42 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusion |
| Q34518160 | Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function |
| Q27638053 | Structure of the Epstein-Barr virus gp42 protein bound to the MHC class II receptor HLA-DR1 |
| Q40214421 | Structure of the Epstein-Barr virus major envelope glycoprotein |
| Q35546891 | Structure-function analysis of varicella-zoster virus glycoprotein H identifies domain-specific roles for fusion and skin tropism |
| Q26995393 | Stuck in the middle: structural insights into the role of the gH/gL heterodimer in herpesvirus entry |
| Q37024812 | Targeted disruption of EBNA1 in EBV-infected cells attenuated cell growth |
| Q37071748 | The BDLF2 protein of Epstein-Barr virus is a type II glycosylated envelope protein whose processing is dependent on coexpression with the BMRF2 protein. |
| Q36945442 | The BDLF3 gene product of Epstein-Barr virus, gp150, mediates non-productive binding to heparan sulfate on epithelial cells and only the binding domain of CD21 is required for infection |
| Q39735571 | The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production |
| Q36499480 | The Epstein-Barr virus BMRF-2 protein facilitates virus attachment to oral epithelial cells |
| Q39669856 | The Epstein-Barr virus latent membrane protein 1 and transforming growth factor--β1 synergistically induce epithelial--mesenchymal transition in lung epithelial cells. |
| Q90069488 | The Epstein-Barr virus nuclear antigen-1 upregulates the cellular antioxidant defense to enable B-cell growth transformation and immortalization |
| Q33984291 | The amino terminus of Epstein-Barr virus glycoprotein gH is important for fusion with epithelial and B cells |
| Q34485104 | The bovine herpesvirus 4 Bo10 gene encodes a nonessential viral envelope protein that regulates viral tropism through both positive and negative effects |
| Q34593942 | The conserved disulfide bond within domain II of Epstein-Barr virus gH has divergent roles in membrane fusion with epithelial cells and B cells |
| Q39685388 | The genes encoding the gCIII complex of human cytomegalovirus exist in highly diverse combinations in clinical isolates |
| Q42274743 | Tousled-like kinases modulate reactivation of gammaherpesviruses from latency |
| Q38921560 | Understanding Epstein-Barr Virus Life Cycle with Proteomics: A Temporal Analysis of Ubiquitination During Virus Reactivation. |
| Q37730214 | Use of gHgL for attachment of Epstein-Barr virus to epithelial cells compromises infection |
| Q39502095 | Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies |
| Q39703319 | α-Helix peptides designed from EBV-gH protein display higher antigenicity and induction of monocyte apoptosis than the native peptide. |
Search more.